Alan D. Brooks
Impact in
- Immunology top 5%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
-
- Phytochemicals and Medicinal Plants
Papers in
-
- Cell death mechanisms and regulation 12
- Ubiquitin and proteasome pathways 4
- Oncology 12
- Cancer-related Molecular Pathways 4
- CAR-T cell therapy research 4
- Co-authors
- Thomas J. Sayers (25 shared papers)Robert H. Wiltrout (5 shared papers)Naoko Seki (4 shared papers)Mark J. Smyth (5 shared papers)Timothy Back (4 shared papers)William J. Murphy (3 shared papers)Peter J. Elliott (2 shared papers)Bruce R. Blazar (2 shared papers)
- Journals
- The Journal of Immunology (6 papers)Vaccine (4 papers)Cancer Research (4 papers)PLoS ONE (2 papers)Cancer Immunology Immunotherapy (2 papers)
- Partner nations
- United StatesSwitzerlandAustralia
In The Last Decade
Alan D. Brooks
48 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 118
- Immunology 563
- Complementary and alternative medicine 129
- Oncology 406
- Health 79
- Cancer Research 130
Countries citing papers authored by Alan D. Brooks
This map shows the geographic impact of Alan D. Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan D. Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan D. Brooks more than expected).
Fields of papers citing papers by Alan D. Brooks
This network shows the impact of papers produced by Alan D. Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan D. Brooks. The network helps show where Alan D. Brooks may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan D. Brooks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 190 | |
| 2 | 2002 | 111 | |
| 3 | Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. | 2003 | 92 |
| 4 | 2012 | 87 | |
| 5 | 2009 | 78 | |
| 6 | 2001 | 77 | |
| 7 | 1998 | 75 | |
| 8 | 2000 | 61 | |
| 9 | 2006 | 59 | |
| 10 | Inhibition of Fas (CD95) expression and Fas-mediated apoptosis by oncogenic Ras. | 1998 | 59 |
| 11 | 2010 | 57 | |
| 12 | 2015 | 50 | |
| 13 | 2017 | 45 | |
| 14 | 2009 | 38 | |
| 15 | 2003 | 35 | |
| 16 | 2008 | 34 | |
| 17 | 2005 | 33 | |
| 18 | 2004 | 32 | |
| 19 | 1990 | 31 | |
| 20 | 2017 | 29 |
About Alan D. Brooks
Alan D. Brooks is a scholar working on Molecular Biology, Oncology, Immunology, Health and Epidemiology, having authored 50 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (12 papers), Vaccine Coverage and Hesitancy (7 papers), Immunotherapy and Immune Responses (7 papers), Phytochemicals and Medicinal Plants (6 papers), Immune Cell Function and Interaction (5 papers), Ubiquitin and proteasome pathways (4 papers), Cancer-related Molecular Pathways (4 papers) and CAR-T cell therapy research (4 papers). The work is most often cited by research in Immunology (563 citations), Complementary and alternative medicine (129 citations), Oncology (406 citations), Health (79 citations) and Cancer Research (130 citations). Alan D. Brooks has collaborated with scholars based in United States, Switzerland and Australia. Frequent co-authors include Thomas J. Sayers, Robert H. Wiltrout, Naoko Seki, Mark J. Smyth, Timothy Back, William J. Murphy, Peter J. Elliott, Bruce R. Blazar, Hideo Yagita∥ and Kristen M. Jacobsen. Their work appears in journals such as The Journal of Immunology, Vaccine, Cancer Research, PLoS ONE and Cancer Immunology Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.